EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies

Kanasap Kaewchim iD, Kittirat Glab-Ampai iD, Kodchakorn Mahasongkram, Thanatsaran Saenlom iD, Watayagorn Thepsawat, Monrat Chulanetra iD, Kiattawee Choowongkomon iD, Nitat Sookrung, Wanpen Chaicumpa iD

Viruses · 2023

DOI: 10.3390/v15061252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Kanasap Kaewchim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Immunology, Department of Immunology, Faculty of Medicine Siriraj Hospital, Bangkok 10700, Thailand. Hauptthemen laut MEDLINE: Single-Domain Antibodies, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Program Management Unit B, Mahidol University, Thailand Ministry of Higher Education, Science, Research, and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Engineered nanobodies (VHs) to the SARS-CoV-2 receptor-binding domain (RBD) were generated using phage display technology. A recombinant Wuhan RBD served as bait in phage panning to fish out nanobody-displaying phages from a VH/VHH phage display library. Sixteen phage-infected E. coli clones produced nanobodies with 81.79–98.96% framework similarity to human antibodies; thus, they may be regarded as human nanobodies. Nanobodies of E. coli clones 114 and 278 neutralized SARS-CoV-2 infectivity in a dose-dependent manner; nanobodies of clones 103 and 105 enhanced the virus’s infectivity by increasing the cytopathic effect (CPE) in an infected Vero E6 monolayer. These four nanobodies also bound to recombinant Delta and Omicron RBDs and native SARS-CoV-2 spike proteins. The neutralizing VH114 epitope contains the previously reported VYAWN motif (Wuhan RBD residues 350–354). The linear epitope of neutralizing VH278 at Wuhan RBD 319RVQPTESIVRFPNITN334 is novel. In this study, for the first time, we report SARS-CoV-2 RBD-enhancing epitopes, i.e., a linear VH103 epitope at RBD residues 359NCVADVSVLYNSAPFFTFKCYG380, and the VH105 epitope, most likely conformational and formed by residues in three RBD regions that are spatially juxtaposed upon the protein folding. Data obtained in this way are useful for the rational design of subunit SARS-CoV-2 vaccines that should be devoid of enhancing epitopes. VH114 and VH278 should be tested further for clinical use against COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesCOVID-19AnimalsHumansSARS-CoV-2EpitopesAntibodies, ViralCOVID-19 VaccinesEscherichia coliAntibodies, NeutralizingSpike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

SARS-CoV-2enhancing epitopenanobody (single-domain antibody/VH/VHH)neutralizing epitopephage displayreceptor-binding domain (RBD)

Substanzen

EpitopesSingle-Domain AntibodiesAntibodies, ViralCOVID-19 VaccinesAntibodies, NeutralizingSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Graduate Program in Immunology, Department of Immunology, Faculty of Medicine Siriraj Hospital, Bangkok 10700, Thailand.
  • Center of Research Excellence in Therapeutic Proteins and Antibody Engineering, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Bangkok 10700, Thailand.
  • Department of Biochemistry, Faculty of Sciences, Kasetsart University, Bangkok 10900, Thailand.
  • Biomedical Research Incubator Unit, Department of Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.

ORCID-Profile: Kanasap Kaewchim, Kittirat Glab-Ampai, Thanatsaran Saenlom, Monrat Chulanetra, Kiattawee Choowongkomon, Wanpen Chaicumpa

Förderung

  • Program Management Unit B
  • Mahidol University
  • Thailand Ministry of Higher Education, Science, Research, and Innovation

Zitieren

APA

Kaewchim, K., Glab-Ampai, K., Mahasongkram, K., Saenlom, T., Thepsawat, W., Chulanetra, M., Choowongkomon, K., Sookrung, N., & Chaicumpa, W. (2023). Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. Viruses. https://doi.org/10.3390/v15061252

Vancouver

Kaewchim K, Glab-Ampai K, Mahasongkram K, Saenlom T, Thepsawat W, Chulanetra M, et al. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. Viruses. 2023. doi:10.3390/v15061252

BibTeX
@article{Kaewchim2023,
  author = {Kaewchim, Kanasap and Glab-Ampai, Kittirat and Mahasongkram, Kodchakorn and Saenlom, Thanatsaran and Thepsawat, Watayagorn and Chulanetra, Monrat and Choowongkomon, Kiattawee and Sookrung, Nitat and Chaicumpa, Wanpen},
  title = {Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15061252}
}
Kostenlos starten →